Goerig N, Fietkau R (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Book Volume: 25
Pages Range: 678-689
Journal Issue: 8
DOI: 10.1007/s00761-019-0546-9
Background: Pancreatic cancer is a tumor with a worldwide incidence of approximately 340,000 newly diagnosed patients per year. With a 5-year overall survival of 2–6% the prognosis is very poor. At the time of diagnosis, resection is the only curative option primarily possible for approximately 30% of the patients. Chemoradiotherapy is a treatment option for achieving resectability of primarily unresectable tumors, improving the results of surgery and also for increasing survival of definitively inoperable patients with advanced states of the disease. Objective: This article gives a current overview on the role of radiotherapy for treatment of pancreatic cancer. Material and methods: Literature analysis of fundamental studies, original and review articles and of current trials. Results: Data from prospective and retrospective analyses show that neoadjuvant chemoradiotherapy of pancreatic cancer increases the number of resectable patients and improves the overall survival. There are comparable data for adjuvant chemoradiotherapy of resected patients with additional risk factors (R1, N +). In cases where resection is definitively impossible, chemoradiotherapy also contributes to local tumor control and improving therapy-free intervals, potentially even to the prognosis. In the palliative setting, irradiation can be used for local pain management. Discussion: The role of radiotherapy as part of multimodal treatment concepts for pancreatic cancer is currently under discussion; however, there are a number of retrospective and prospective studies clearly suggesting the benefits of radiotherapy in addition to surgery and chemotherapy. Prospective studies are necessary for further verification using modern techniques for radiotherapy, such as stereotactic and intensity-modulated radiotherapy. The use of older studies, with inadequate irradiation techniques and obsolete doses from today’s point of view, for evaluating the effects of radiotherapy is not acceptable.
APA:
Goerig, N., & Fietkau, R. (2019). Rolle der Radiotherapie beim Pankreaskarzinom. Onkologe, 25(8), 678-689. https://doi.org/10.1007/s00761-019-0546-9
MLA:
Goerig, Nicole, and Rainer Fietkau. "Rolle der Radiotherapie beim Pankreaskarzinom." Onkologe 25.8 (2019): 678-689.
BibTeX: Download